<DOC>
	<DOCNO>NCT00118339</DOCNO>
	<brief_summary>RATIONALE : Chemoprotective agent may protect normal cell side effect chemotherapy . Ice chip saline mouth rinse may lessen severity help prevent symptom mucositis mouth sore patient receive melphalan autologous stem cell transplant multiple myeloma . It yet know whether ice chip effective saline mouth rinse reduce prevent mucositis . PURPOSE : This randomized phase III trial study ice chip see well work compare saline mouth rinse reduce prevent mucositis patient receive melphalan autologous stem cell transplant multiple myeloma .</brief_summary>
	<brief_title>Ice Chips Saline Mouth Rinse Reducing Preventing Mucositis Patients Receiving Melphalan Autologous Stem Cell Transplant Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy administer ice chip vs room temperature normal saline oral rinse , , melphalan administration , term reduce eliminate grade 3 4 oral mucositis , patient undergo autologous peripheral blood stem cell transplantation ( PBSCT ) multiple myeloma . - Compare number day IV narcotic therapy require oral mucositis pain patient treat regimen . - Compare use IV hydration and/or total parenteral nutrition autologous PBSCT patient treat regimen . - Compare overall quality life , term ability eat food drink liquid , patient treat regimen . OUTLINE : This randomize , pilot study . Patients stratify accord age ( less 60 year vs 60 year ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral ice chip 15 minute , , 8 hour melphalan infusion* day -2 . - Arm II : Patients receive room temperature normal saline oral rinse 30 second 15 minute , , 8 hour melphalan infusion* day -2 . All patient undergo autologous peripheral blood stem cell transplantation ( PBSCT ) * day 0 . NOTE : *Patients receive melphalan infusion undergo autologous PBSCT protocol FHCRC-1137.00 . Quality life assess 3 day week 4 week . After completion study treatment , patient follow 28 day periodically thereafter . PROJECTED ACCRUAL : A total 40 patient ( 20 per treatment arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Scheduled undergo autologous peripheral blood stem cell transplantation ( PBSCT ) multiple myeloma protocol FHCRC1137.00 Scheduled receive regimen singleagent melphalan dose 200 mg/m^2 PBSCT PATIENT CHARACTERISTICS : Age Over 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent artificial saliva day melphalan infusion ( day 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>oral complication</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>